Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
Authors:
Open Access
- 1 October 2023
- journal article
- editorial
- Published by Taylor & Francis in Open Access Rheumatology: Research and Reviews
- Vol. ume 15, 207-212
Abstract
This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The article also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis.Keywords
This publication has 11 references indexed in Scilit:
- An online survey among US patients with immune-mediated conditions: Attitudes about biosimilarsJournal of Managed Care & Specialty Pharmacy, 2023
- Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European CountriesRheumatology and Therapy, 2023
- Overview of biosimilars for immune-mediated inflammatory diseases: summary of current evidenceThe American Journal of Managed Care, 2022
- Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trialAnnals of the Rheumatic Diseases, 2021
- Switching between reference adalimumab and biosimilars in chronic immune‐mediated inflammatory diseases: A systematic literature reviewBritish Journal of Clinical Pharmacology, 2021
- Outcomes following biosimilar TNF inhibitor use for inflammatory-mediated immune disorders in pregnancyObstetric Medicine, 2021
- Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effectsRMD Open, 2021
- Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the RoadFrontiers in Pharmacology, 2021
- Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance databaseRheumatology, 2020
- Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence studyAnnals of the Rheumatic Diseases, 2018